This product is no longer available in the United States. For a similar product, please see BisulFlash DNA Modification Kit





The Methylamp™ One-Step DNA Modification Kit is a complete set of essential components which enables the experimenter to perform DNA methylation analysis using Epigentek's uniquely simplified and streamlined bisulfite method. The entire procedure can be completed within a mere 1 hour and 45 minutes and produces far superior results than any competitor kits. The Methylamp™ One-Step DNA Modification Kit is suitable for MS-PCR, real time MS-PCR, methylation sequencing, and pyrosequencing, as well as methylation microarray.

WHY CHOOSE THE METHYLAMP™ ONE-STEP DNA MODIFICATION KIT?

• The number one fastest procedure available. The entire experiment can be finished within 1 hour and 45 minutes.
• Completely converts unmethylated cytosine into uracil: modified DNA > 99.98%.
• The lowest degradation of DNA in the modification process: more than 90% of DNA loss can be prevented.
• The lowest requirement of starting DNA for modification: only 50 pg or 20 cells.
• Extremely simple, reliable, and consistent modification conditions.

The Methylamp™ One-Step DNA Modification Kit contains all reagents required for bisulfite conversion on a DNA sample. DNA is denatured by heating, which allows DNA denaturation and bisulfite modification to be carried out simultaneously. In the modification process, bisulfite reagent reacts specifically with single-stranded DNA, thereby deaminating cytosine and creating a uracil residue. The unique DNA protection reagents contained in the modification buffer can prevent the chemical and thermophilic degradation of DNA in the bisulfite treatment. The non-toxic modified DNA capture buffer enables DNA to tightly bind to the column filter, thus DNA cleaning can be carried out on the column to effectively remove residual sodium bisulfite and salts. Modified DNA then can be eluted and stably stored at -20°C for up to 2 months.

SCHEMATIC PROCEDURE:	COMPARATIVE OVERVIEW:

G1 (DNA Modification Powder)
G2 (DNA Modification)
G3 (Balance Solution)
G4 (Modified DNA Capture)
G5 (Modified DNA Cleaning)
G6 (Modified DNA Elution)
F-Spin Column
F-Collection Tube
User Guide

[User Guide]* *Always use the actual User Guide that shipped with your product. Is the above file locked? You can also request user guides by emailing info@epigentek.com along with your contact information and institution name.

[Material Safety Data Sheet]

Gallardo, A. et. al. (April 2012). Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas. Br J Cancer. 106(8):1367-73. PubMed Abstract

Yuasa, Y. et. al. (March 2012). IGF2 hypomethylation of blood leukocyte DNA is associated with gastric cancer risk. Int J Cancer. Epub ahead of print. PubMed Abstract

Thathia, SH. et. al. (March 2012). Epigenetic inactivation of TWIST2 in acute lymphoblastic leukemia modulates proliferation, cell survival and chemosensitivity. Haematologica. 97(3):371-8. PubMed Abstract

Calabuig-Fariñas, S. et. al. (February 2012). Characterization of a New Human Cell Line (CH-3573) Derived from a Grade II Chondrosarcoma with Matrix Production. Pathol Oncol Res. Epub ahead of print. PubMed Abstract

Thathia, SH. et. al. (November 2011). Epigenetic inactivation of TWIST2 in acute lymphoblastic leukemia modulates proliferation, cell survival and chemosensitivity. Haematologica. Epub ahead of print. PubMed Abstract

Ferguson, S. et. al. (March 2011). The dual role of HLXB9 in leukemia. Pediatric Blood & Cancer. 56(3): 349-52. PubMed Abstract

Pang, J. C. et. al. (April 2010). KIAA0495/PDAM Is Frequently Downregulated in Oligodendroglial Tumors and Its Knockdown by siRNA Induces Cisplatin Resistance in Glioma Cells. Brain Pathology. 20(6):1021-32. PubMed Abstract

Cheng, Z. D. et. al. (February 2010). Promoter methylation of CHFR gene in gastric carcinoma tissues detected using two methods. Chinese Journal of Cancer. 29(2): 163-7. Full PDF Article

Novara, F. et. al. (October 2009). Different molecular mechanisms causing 9p21 deletions in acute lymphoblastic leukemia of childhood. Hum Genet. 126(4): 511–520. Full PDF Article

Cheetham, S. et. al. (June 2008). SPARC promoter hypermethylation in colorectal cancers can be reversed by 5-Aza-2'deoxycytidine to increase SPARC expression and improve therapy response. British Journal of Cancer. 98(11): 1810-9. PubMed Abstract

Otsubo, T. et. al. (July 2007). SOX2 is frequently downregulated in gastric cancers and inhibits cell growth through cell-cycle arrest and apoptosis. British Journal of Cancer. 98(4): 824-31. PubMed Abstract

Treilleux, I. et. al. (July 2007). The molecular causes of low ATM protein expression in breast carcinoma; promoter methylation and levels of the catalytic subunit of DNA-dependent protein kinase. Histopathology. 51(1): 63-9. PubMed Abstract